Trial Profile
Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Haemochromatosis; Myelodysplastic syndromes
- Focus Biomarker; Therapeutic Use
- Acronyms DefeHEMY
- 02 Apr 2024 Status changed from discontinued to withdrawn prior to enrolment.
- 20 Jan 2017 Status changed from recruiting to discontinued.
- 25 May 2015 New trial record